Skip to main content
Log in

BIRB-796 is not an effective ABL(T315I) inhibitor

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Nagar, B. et al. Cancer Res. 62, 4236–4243 (2002).

    CAS  PubMed  Google Scholar 

  2. O'Hare, T. et al. Blood 104, 2532–2539 (2004).

    Article  CAS  PubMed  Google Scholar 

  3. Seggewiss, R. et al. Blood 105, 2473–2479 (2005).

    Article  CAS  PubMed  Google Scholar 

  4. O'Hare, T., Walters, D.K., Deininger, M.W. & Druker, B.J. Cancer Cell 7, 117–119 (2005).

    Article  CAS  PubMed  Google Scholar 

  5. Weisberg, E. et al. Cancer Cell 7, 129–141 (2005).

    Article  CAS  PubMed  Google Scholar 

  6. Shah, N.P. et al. Science 305, 399–401 (2004).

    Article  CAS  PubMed  Google Scholar 

  7. O'Hare, T. et al. Cancer Res. 65, 4500–4505 (2005).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian J. Druker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Hare, T., Druker, B. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol 23, 1209–1210 (2005). https://doi.org/10.1038/nbt1005-1209

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1005-1209

  • Springer Nature America, Inc.

This article is cited by

Navigation